Developer docs
API playgroundTry for free, no card

Search company profiles

Trius Therapeutics

Full company profile

uuid003q41o

Namestring
Trius Therapeutics
Websiteurl
triusrx.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Trius Therapeutics is a biopharmaceutical company founded in 2004 and headquartered in Lexington, Massachusetts, focused on the development of innovative antibiotics for life-threatening infections. The company operated as a clinical-stage therapeutics developer, advancing small-molecule antibacterial compounds through preclinical and clinical development toward regulatory approval and commercialization in the acute-care hospital setting. Its business model was the classic clinical-stage biotech archetype: raise venture capital in staged rounds, progress a lead asset through clinical trials, and either launch commercially or transact via acquisition or partnership. No product names, clinical-trial readouts, regulatory milestones, or approved assets are documented in the input data, so the specific lead compound and its development status cannot be confirmed from the available material.

The company executed a multi-year venture-funding program spanning 2006 through 2013, raising a disclosed total of approximately $99.25 million across at least five rounds. Institutional capital came from recognized biotech venture investors including Sofinnova Investments (which led the 2007 Series 2), InterWest Partners, and Versant Ventures, with earlier-stage participation from TCA Venture Group. The 2007 round of $20 million was the first major institutional event, and subsequent rounds in 2009, 2011, and 2013 reflect a sustained capital cadence consistent with advancement of a clinical asset. Leadership at the time comprised Jeffrey Stein as President & CEO, David Kabakoff as Chairman of the Board, and Craig Thompson as Chief Commercial Officer — a team structure consistent with a company preparing for either a commercial launch or a strategic exit.

Trius Therapeutics was listed on NASDAQ under ticker TSRX and is currently classified as delisted, consistent with the company having been acquired and absorbed by a larger acquirer. The original website (triusrx.com) no longer carries substantive content. No pricing, distribution, customer, partnership, or product-portfolio data is available in the input, so the company's commercial mechanics, partner ecosystem, and any approved or marketed products cannot be characterized from this dataset. The 1,001-5,000 employee headcount figure in the firmographic data is inconsistent with a clinical-stage biotech of this profile and funding scale, and should be treated with low confidence.

Short descriptiontext

Trius Therapeutics is a biopharmaceutical company founded in 2004, headquartered in Lexington, Massachusetts, that developed innovative antibiotics for life-threatening infections. It operated as a clinical-stage biotech and is now delisted following acquisition.

Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
antibiotic drug development, infectious disease therapeutics, novel antibiotic compounds, antimicrobial pharmaceutical research, life-threatening infection treatment
Industry2 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAFAG
Microbiome Modulating Small Molecules & Antibiotic Alternatives
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Infectious Disease Pharmaceuticals
Social media profiles2 records
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Trius Therapeutics develops innovative antibiotics for the treatment of life-threatening bacterial infections. The company focuses on discovering and advancing novel antimicrobial compounds to address serious infectious diseases, with emphasis on therapies for drug-resistant pathogens.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Innovative antibiotic therapies for life-threatening infections
CategoryInfectious Disease Pharmaceuticals
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage antibiotics developer (iclaprim) targeting acute bacterial skin infections. Comparable in single-asset, late-stage antibiotics focus, though smaller and UK-listed.

TypeDirect peer
Description

Clinical-stage antibiotics developer targeting multi-drug resistant gram-negative infections. Comparable in therapeutic focus, stage of development, and capital intensity, with a similar NASDAQ-listed trajectory.

3Nabriva Therapeutics
TypeDirect peer
Description

Developer of lefamulin, a first-in-class pleuromutilin antibiotic for community-acquired bacterial pneumonia. Comparable in antibiotic specialty positioning, single-asset development model, and hospital-channel go-to-market.

4Optimer Pharmaceuticals
TypeDirect peer
Description

Late-stage antibiotics developer focused on hospital infections (fidaxomicin/DIFICID for C. difficile). Direct comparable in business model — single-asset, hospital-channel antibiotic launches with similar regulatory and stewardship dynamics.

TypeBroad incumbent
Description

Acquired Cubist Pharmaceuticals and inherited its antibiotics franchise. Relevant incumbent comparator for hospital antibiotics commercial dynamics and a key benchmark for strategic-exit valuation in this category.

TypeDirect peer
Description

Developer of delafloxacin and other antibiotics targeting serious bacterial infections. Direct comparable as a specialty antibiotics commercial-stage company with similar hospital-channel positioning.

TypeDirect peer
Description

Developed eravacycline, a synthetic tetracycline antibiotic for complicated intra-abdominal and urinary tract infections. Closely comparable in clinical-stage antibiotic development, regulatory pathway, and commercial channel.

TypeDirect peer
Description

Developer of tetracycline-class antibiotics (omadacycline, sarecycline) targeting serious community-acquired infections. Directly comparable in therapeutic focus on differentiated antibiotics against resistant pathogens.

9Cubist Pharmaceuticals
TypeBroad incumbent
Description

Established hospital-antibiotics company that was a direct strategic acquirer in the space and built its franchise around daptomycin. Highly comparable to Trius as the lead acquirer/integrator of innovative gram-positive antibiotics.

10Cempra
TypeDirect peer
Description

Developed solithromycin for community-acquired bacterial pneumonia and fusidic acid for acute bacterial skin infections. Closely comparable single-asset antibiotics developer with similar regulatory pathway and hospital/specialty channel dynamics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Trius Therapeutics

Infectious Disease Pharmaceuticalstriusrx.com

Trius Therapeutics is a biopharmaceutical company founded in 2004, headquartered in Lexington, Massachusetts, that developed innovative antibiotics for life-threatening infections. It operated as a clinical-stage biotech and is now delisted following acquisition.

What Trius Therapeutics does

Trius Therapeutics is a biopharmaceutical company founded in 2004 and headquartered in Lexington, Massachusetts, focused on the development of innovative antibiotics for life-threatening infections. The company operated as a clinical-stage therapeutics developer, advancing small-molecule antibacterial compounds through preclinical and clinical development toward regulatory approval and commercialization in the acute-care hospital setting. Its business model was the classic clinical-stage biotech archetype: raise venture capital in staged rounds, progress a lead asset through clinical trials, and either launch commercially or transact via acquisition or partnership. No product names, clinical-trial readouts, regulatory milestones, or approved assets are documented in the input data, so the specific lead compound and its development status cannot be confirmed from the available material.

The company executed a multi-year venture-funding program spanning 2006 through 2013, raising a disclosed total of approximately $99.25 million across at least five rounds. Institutional capital came from recognized biotech venture investors including Sofinnova Investments (which led the 2007 Series 2), InterWest Partners, and Versant Ventures, with earlier-stage participation from TCA Venture Group. The 2007 round of $20 million was the first major institutional event, and subsequent rounds in 2009, 2011, and 2013 reflect a sustained capital cadence consistent with advancement of a clinical asset. Leadership at the time comprised Jeffrey Stein as President & CEO, David Kabakoff as Chairman of the Board, and Craig Thompson as Chief Commercial Officer — a team structure consistent with a company preparing for either a commercial launch or a strategic exit.

Trius Therapeutics was listed on NASDAQ under ticker TSRX and is currently classified as delisted, consistent with the company having been acquired and absorbed by a larger acquirer. The original website (triusrx.com) no longer carries substantive content. No pricing, distribution, customer, partnership, or product-portfolio data is available in the input, so the company's commercial mechanics, partner ecosystem, and any approved or marketed products cannot be characterized from this dataset. The 1,001-5,000 employee headcount figure in the firmographic data is inconsistent with a clinical-stage biotech of this profile and funding scale, and should be treated with low confidence.

Trius Therapeutics firmographics

Firmographics
Name
Trius Therapeutics
Website
https://triusrx.com
Company type
Private
Founded year
2004
Headcount range
1,001–5,000 employees
Short description
Trius Therapeutics is a biopharmaceutical company founded in 2004, headquartered in Lexington, Massachusetts, that developed innovative antibiotics for life-threatening infections. It operated as a clinical-stage biotech and is now delisted following acquisition.
Ownership category
akta.pro rank

Trius Therapeutics industry classification

Industry
Product category
Infectious Disease Pharmaceuticals
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAFAG
Microbiome Modulating Small Molecules & Antibiotic Alternatives

Keywords

  • Antibiotic drug development
  • Infectious disease therapeutics
  • Novel antibiotic compounds
  • Antimicrobial pharmaceutical research
  • Life-threatening infection treatment

Where Trius Therapeutics is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Markets served

Trius Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Trius Therapeutics product offering

Product offering

Core offering

Trius Therapeutics develops innovative antibiotics for the treatment of life-threatening bacterial infections. The company focuses on discovering and advancing novel antimicrobial compounds to address serious infectious diseases, with emphasis on therapies for drug-resistant pathogens.

Differentiator

Problem solved

Functional benefit

Products and services

  • Innovative antibiotic therapies for life-threatening infections

Companies that use Trius Therapeutics

Customer profile

Ideal customer profiles2 records

Trius Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Trius Therapeutics partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights4 records

Trius Therapeutics competitors and assessment

Company assessment

Emerging players

  • Motif Bio: Clinical-stage antibiotics developer (iclaprim) targeting acute bacterial skin infections. Comparable in single-asset, late-stage antibiotics focus, though smaller and UK-listed.

Direct peers

  • Achaogen: Clinical-stage antibiotics developer targeting multi-drug resistant gram-negative infections. Comparable in therapeutic focus, stage of development, and capital intensity, with a similar NASDAQ-listed trajectory.
  • Nabriva Therapeutics: Developer of lefamulin, a first-in-class pleuromutilin antibiotic for community-acquired bacterial pneumonia. Comparable in antibiotic specialty positioning, single-asset development model, and hospital-channel go-to-market.
  • Optimer Pharmaceuticals: Late-stage antibiotics developer focused on hospital infections (fidaxomicin/DIFICID for C. difficile). Direct comparable in business model — single-asset, hospital-channel antibiotic launches with similar regulatory and stewardship dynamics.
  • Melinta Therapeutics: Developer of delafloxacin and other antibiotics targeting serious bacterial infections. Direct comparable as a specialty antibiotics commercial-stage company with similar hospital-channel positioning.
  • Tetraphase Biosciences: Developed eravacycline, a synthetic tetracycline antibiotic for complicated intra-abdominal and urinary tract infections. Closely comparable in clinical-stage antibiotic development, regulatory pathway, and commercial channel.
  • Paratek Pharmaceuticals: Developer of tetracycline-class antibiotics (omadacycline, sarecycline) targeting serious community-acquired infections. Directly comparable in therapeutic focus on differentiated antibiotics against resistant pathogens.
  • Cempra: Developed solithromycin for community-acquired bacterial pneumonia and fusidic acid for acute bacterial skin infections. Closely comparable single-asset antibiotics developer with similar regulatory pathway and hospital/specialty channel dynamics.

Broad incumbents

  • Merck & Co. (Cubist successor): Acquired Cubist Pharmaceuticals and inherited its antibiotics franchise. Relevant incumbent comparator for hospital antibiotics commercial dynamics and a key benchmark for strategic-exit valuation in this category.
  • Cubist Pharmaceuticals: Established hospital-antibiotics company that was a direct strategic acquirer in the space and built its franchise around daptomycin. Highly comparable to Trius as the lead acquirer/integrator of innovative gram-positive antibiotics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Trius Therapeutics social profiles

Digital presence

Trius Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Trius Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

Trius Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Trius Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trius Therapeutics

What does Trius Therapeutics do?

Trius Therapeutics develops innovative antibiotics for the treatment of life-threatening bacterial infections. The company focuses on discovering and advancing novel antimicrobial compounds to address serious infectious diseases, with emphasis on therapies for drug-resistant pathogens.

When was Trius Therapeutics founded?

Trius Therapeutics was founded in 2004. It employs 1,001 to 5,000 people.

Where is Trius Therapeutics based?

Trius Therapeutics is headquartered in Lexington, United States, in the North America region.

Who are Trius Therapeutics's main competitors?

Motif Bio is listed as an emerging player. Direct peers are Achaogen, Nabriva Therapeutics, Optimer Pharmaceuticals, Melinta Therapeutics, Tetraphase Biosciences, Paratek Pharmaceuticals and Cempra. Broad incumbents are Merck & Co. (Cubist successor) and Cubist Pharmaceuticals.

Does Trius Therapeutics have an API?

No public API is recorded for Trius Therapeutics.

What industry is Trius Therapeutics in?

Trius Therapeutics's product category is Infectious Disease Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAAAFAG, Microbiome Modulating Small Molecules & Antibiotic Alternatives. Its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireForge Therapeutics Attracts Biotechnology Leaders To Join Expanded Board Of DirectorsForge Therapeutics expanded its board of directors with new members, including Mario Polywka, John Schmid, Stephen Worland, Brian Dorsey, and Zachary Zimmerman. The expansion follows the company's $8.8M CARB-X research award and $15M Series A financing. The board will provide strategic guidance as Forge advances its antibiotic pipeline.socaltech.comAnaptysBio Names Board MembersAnaptysBio named Hollings Renton and John Schmid to its board. Renton, former CEO of Onyx Pharmaceuticals, and Schmid, former CFO of Auspex Pharmaceuticals, were added to bring strategic planning and corporate finance expertise. Renton also serves on the boards of Portola Pharmaceuticals, Cepheid, and Kythera Biopharmaceuticals.GlobeNewswireTrius Therapeutics, Inc. Announces Exercise of Underwriters' Option to Purchase Additional Shares for Common Stock OfferingTrius Therapeutics announced that underwriters exercised their option to buy an additional 869,135 shares in its Jan. 17 public offering, bringing total shares sold to 7,169,135 at $4.75 each. Expected gross proceeds are about $34.1 million, to be used for clinical trials, R&D, and working capital. The offering is expected to close on Jan. 24, 2013.GlobeNewswireTrius Therapeutics, Inc. Prices Public Offering of Common StockTrius Therapeutics priced an underwritten public offering of 6.3 million common shares at $4.75 per share, with gross proceeds expected to be approximately $29.925 million before underwriting discounts and expenses. The offering is expected to close on or about January 24, 2013, and the company plans to use net proceeds for general corporate purposes, including clinical trial and research expenses.GlobeNewswireTrius Therapeutics, Inc. Announces Proposed Public Offering of Common StockTrius Therapeutics announced a proposed underwritten public offering of common stock, with Citigroup and Leerink Swann as joint book-running managers and Baird as co-lead manager. The offering is subject to market conditions and filed under two SEC shelf registration statements. The company's lead drug, tedizolid phosphate, is in Phase 3 for serious gram-positive infections.GlobeNewswireTrius Therapeutics, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares for Common Stock OfferingTrius Therapeutics announced that underwriters exercised their option to buy an additional 1,290,000 shares at $5.25 each, bringing expected gross proceeds to about $51.9 million. The offering, including the additional shares, is expected to close on January 31, 2012. Proceeds will be used for general corporate purposes, including clinical trials and R&D.GlobeNewswireTrius Therapeutics, Inc. Prices Public Offering of Common StockTrius Therapeutics priced an underwritten public offering of 8.6 million common shares at $5.25 per share, with gross proceeds expected near $45.2 million before expenses. The offering is expected to close on January 31, 2012, and net proceeds will fund clinical trials, R&D, and general corporate purposes.GlobeNewswireTrius Therapeutics, Inc. Announces Proposed Public Offering of Common StockTrius Therapeutics announced a proposed underwritten public offering of common stock, with Citigroup and Piper Jaffray as joint book-running managers. The offering is subject to market conditions and filed under a shelf registration statement effective September 15, 2011.